Milica Kontic
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Milica Kontic has a total of 483 co-authors. Here are the top co-authors by number of shared publications:
- Beata Świątkowska
Department of Environmental Epidemiology, Nofer Institute of Occupational Medicine, Łódź, Poland
40 shared publications - Jolanta Lissowska
Department of Cancer Epidemiology and Primary Prevention, Maria Skłodowska-Curie National Research Institute of Oncology, Warshaw, Poland
40 shared publications Anush Mukeria
38 shared publications- Geoffrey Liu
Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre/University Health Network, University of Toronto, Toronto, ON M5G 2C4, Canada
38 shared publications - Matthew B. Schabath
H. Lee Moffitt Cancer Center and Research Institute
38 shared publications - Angela Cecilia Pesatori
Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy
37 shared publications
Latest Publications
- Open Access
- 23 October 2026
- Published by Discovery Medicine in Discovery Medicine
- Vol. 38 (213) , 3187-3196
When Brain Metastases Meet Immunotherapy: Real-World Outcomes With First-Line Pembrolizumab in PD-L1-High Metastatic NSCLC
Background: Although immune checkpoint inhibitors (ICI) have revolutionized the treatment landscape for patients with non-small cell lung cancer (NSCLC), the impact on brain metastases (BM) remains uncertain, as these patients have often been excluded from or underrepresented in clinical trials. The aim of this study was to investigate the association between metastatic site and response to immunotherapy.Methods: This retrospective single-center study included 141 consecutive adults with advanced NSCLC, programmed death ligand 1 (PD-L1) tumor proportion score ≥50%, Eastern Cooperative Oncology Group (ECOG) performance status 0–1, and no activating epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) rearrangement who received first-line pembrolizumab monotherapy between 2018 and 2022. Patients with BM received stereotactic radiosurgery or whole-brain radiotherapy before or in parallel with pembrolizumab according to multidisciplinary recommendations. Survival was analyzed using Kaplan-Meier estimates, log-rank testing, and Cox proportional hazards models. Because metastatic-site coding was available only for patients with documented distant metastases, the site-specific BM versus other metastatic site comparison was restricted to a 115-patient subset.Results: The full cohort comprised 141 analyzable patients. In the primary metastatic-site subset (n = 115), 28 patients had BM and 87 had other metastatic sites without BM. In this subset, progression-free survival (PFS) was longer in the BM group than in the non-BM metastatic-site group (hazard ratio [HR] 0.42, (95% CI 0.19–0.94; p = 0.035)). Median PFS was not reached in the BM group (95% CI 14.0 months to not reached) and was 26.0 months (95% CI 8.0 months to not reached) in the non-BM group. Overall survival (OS) did not differ significantly (HR 0.48, 95% CI 0.21–1.09; p = 0.080); the median OS was not reached in the BM group (95% CI 14.0 months to not reached) and was 30.0 months (95% CI 15.0–40.0 months) in the non-BM group.Conclusion: In this retrospective cohort, patients with BM who received pembrolizumab plus local CNS-directed radiotherapy had longer PFS than patients with other metastatic sites, but no statistically significant OS advantage. These findings should be interpreted cautiously because all BM patients received local radiotherapy and had lower extracranial metastatic burden; the observed PFS difference may reflect treatment-related confounding, selection bias, and baseline prognostic imbalance rather than intrinsic sensitivity of brain metastases to immunotherapy.
- 23 October 2026
- Published by Discovery Medicine in Discovery Medicine
- Vol. 38 (213) , 3187-3196
Open AccessWhen Brain Metastases Meet Immunotherapy: Real-World Outcomes With First-Line Pembrolizumab in PD-L1-High Metastatic NSCLC
Background: Although immune checkpoint inhibitors (ICI) have revolutionized the treatment landscape for patients with non-small cell lung cancer (NSCLC), the impact on brain metastases (BM) remains uncertain, as these patients have often been excluded from or underrepresented in clinical trials. The aim of this study was to investigate the association between metastatic site and response to immunotherapy.Methods: This retrospective single-center study included 141 consecutive adults with advanced NSCLC, programmed death ligand 1 (PD-L1) tumor proportion score ≥50%, Eastern Cooperative Oncology Group (ECOG) performance status 0–1, and no activating epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) rearrangement who received first-line pembrolizumab monotherapy between 2018 and 2022. Patients with BM received stereotactic radiosurgery or whole-brain radiotherapy before or in parallel with pembrolizumab according to multidisciplinary recommendations. Survival was analyzed using Kaplan-Meier estimates, log-rank testing, and Cox proportional hazards models. Because metastatic-site coding was available only for patients with documented distant metastases, the site-specific BM versus other metastatic site comparison was restricted to a 115-patient subset.Results: The full cohort comprised 141 analyzable patients. In the primary metastatic-site subset (n = 115), 28 patients had BM and 87 had other metastatic sites without BM. In this subset, progression-free survival (PFS) was longer in the BM group than in the non-BM metastatic-site group (hazard ratio [HR] 0.42, (95% CI 0.19–0.94; p = 0.035)). Median PFS was not reached in the BM group (95% CI 14.0 months to not reached) and was 26.0 months (95% CI 8.0 months to not reached) in the non-BM group. Overall survival (OS) did not differ significantly (HR 0.48, 95% CI 0.21–1.09; p = 0.080); the median OS was not reached in the BM group (95% CI 14.0 months to not reached) and was 30.0 months (95% CI 15.0–40.0 months) in the non-BM group.Conclusion: In this retrospective cohort, patients with BM who received pembrolizumab plus local CNS-directed radiotherapy had longer PFS than patients with other metastatic sites, but no statistically significant OS advantage. These findings should be interpreted cautiously because all BM patients received local radiotherapy and had lower extracranial metastatic burden; the observed PFS difference may reflect treatment-related confounding, selection bias, and baseline prognostic imbalance rather than intrinsic sensitivity of brain metastases to immunotherapy.
- Open Access
Real-World Comparison of PD-1 and PD-L1 Inhibitor Monotherapy in Metastatic Non-Small Cell Lung Cancer with High PD-L1 Expression
Background: Immune checkpoint inhibitor monotherapy targeting the PD-1/PD-L1 axis is a standard first-line treatment option for patients with metastatic non-small cell lung cancer (NSCLC) and high PD-L1 expression. However, comparative real-world data evaluating PD-1 versus PD-L1 inhibitor monotherapy in this population remain limited. Methods: We conducted a retrospective, single-center real-world analysis of patients with metastatic NSCLC and high PD-L1 expression who initiated first-line immune checkpoint inhibitor monotherapy between May 2024 and January 2025. Patients were treated with either pembrolizumab (PD-1 inhibitor) or atezolizumab (PD-L1 inhibitor) as monotherapy. Progression-free survival (PFS) was estimated using the Kaplan–Meier method and compared using the log-rank test. Univariable and multivariable Cox proportional hazards regression models were applied to identify clinical factors associated with PFS. Results: A total of 125 patients were included, of whom 73 received pembrolizumab and 52 received atezolizumab. The median PFS was numerically longer in patients treated with pembrolizumab compared with atezolizumab (9.93 vs. 5.33 months), although this difference did not reach statistical significance (HR 1.14, 95% CI 0.74–1.74; p = 0.559). Poor performance status (ECOG PS 2) was independently associated with inferior PFS (HR 3.22, 95% CI 2.02–5.12), whereas very high PD-L1 expression (TPS 90–100%) was independently associated with improved PFS (HR 0.57, 95% CI 0.35–0.93). Conclusions: In this real-world cohort, pembrolizumab was associated with numerically longer PFS than atezolizumab; however, this difference was not statistically significant. Outcomes were primarily driven by baseline clinical factors, particularly performance status and the degree of PD-L1 expression. Larger cohorts with longer follow-up are warranted to clarify potential differences and assess long-term outcomes.
Open AccessReal-World Comparison of PD-1 and PD-L1 Inhibitor Monotherapy in Metastatic Non-Small Cell Lung Cancer with High PD-L1 Expression
Background: Immune checkpoint inhibitor monotherapy targeting the PD-1/PD-L1 axis is a standard first-line treatment option for patients with metastatic non-small cell lung cancer (NSCLC) and high PD-L1 expression. However, comparative real-world data evaluating PD-1 versus PD-L1 inhibitor monotherapy in this population remain limited. Methods: We conducted a retrospective, single-center real-world analysis of patients with metastatic NSCLC and high PD-L1 expression who initiated first-line immune checkpoint inhibitor monotherapy between May 2024 and January 2025. Patients were treated with either pembrolizumab (PD-1 inhibitor) or atezolizumab (PD-L1 inhibitor) as monotherapy. Progression-free survival (PFS) was estimated using the Kaplan–Meier method and compared using the log-rank test. Univariable and multivariable Cox proportional hazards regression models were applied to identify clinical factors associated with PFS. Results: A total of 125 patients were included, of whom 73 received pembrolizumab and 52 received atezolizumab. The median PFS was numerically longer in patients treated with pembrolizumab compared with atezolizumab (9.93 vs. 5.33 months), although this difference did not reach statistical significance (HR 1.14, 95% CI 0.74–1.74; p = 0.559). Poor performance status (ECOG PS 2) was independently associated with inferior PFS (HR 3.22, 95% CI 2.02–5.12), whereas very high PD-L1 expression (TPS 90–100%) was independently associated with improved PFS (HR 0.57, 95% CI 0.35–0.93). Conclusions: In this real-world cohort, pembrolizumab was associated with numerically longer PFS than atezolizumab; however, this difference was not statistically significant. Outcomes were primarily driven by baseline clinical factors, particularly performance status and the degree of PD-L1 expression. Larger cohorts with longer follow-up are warranted to clarify potential differences and assess long-term outcomes.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S23 from A Prognostic Signature for Lung Adenocarcinoma in Patients Who Have Never Smoked
Supplementary Figure S23 shows heatmap columns that define enriched pathways and rows define signature genes. Enrichment significance is indicated by color intensity. The annotation bar on the top denotes the gene databases used for the enrichment test, and the annotation bar on the right indicates the subtypes of signature genes. Signature genes not associated with any significantly enriched pathway are listed at the bottom of the heatmap.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S23 from A Prognostic Signature for Lung Adenocarcinoma in Patients Who Have Never Smoked
Supplementary Figure S23 shows heatmap columns that define enriched pathways and rows define signature genes. Enrichment significance is indicated by color intensity. The annotation bar on the top denotes the gene databases used for the enrichment test, and the annotation bar on the right indicates the subtypes of signature genes. Signature genes not associated with any significantly enriched pathway are listed at the bottom of the heatmap.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S21 from A Prognostic Signature for Lung Adenocarcinoma in Patients Who Have Never Smoked
Supplementary Figure S21 shows (A) Estimation of the minimum gene set per NS-LUAD expression subtype by cross validation in the Sherlock cohort, evaluating 1 to 30 genes per subtype. Box plots show the number of genes per NS-LUAD subtype (x-axis) versus cross-validation error rates (y-axis). (B) Distribution of the error rates for predicting NS-LUAD expression subtypes using the 60-gene signature by cross validation in the Sherlock cohort. Training and testing set error rates are indicated by colors, and median values are marked by dashed lines.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S21 from A Prognostic Signature for Lung Adenocarcinoma in Patients Who Have Never Smoked
Supplementary Figure S21 shows (A) Estimation of the minimum gene set per NS-LUAD expression subtype by cross validation in the Sherlock cohort, evaluating 1 to 30 genes per subtype. Box plots show the number of genes per NS-LUAD subtype (x-axis) versus cross-validation error rates (y-axis). (B) Distribution of the error rates for predicting NS-LUAD expression subtypes using the 60-gene signature by cross validation in the Sherlock cohort. Training and testing set error rates are indicated by colors, and median values are marked by dashed lines.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S19 from A Prognostic Signature for Lung Adenocarcinoma in Patients Who Have Never Smoked
Supplementary Figure S19 shows (A) Comparison of TIDE scores predicting response to ICB across NS-LUAD expression subtypes. B-E, Comparison of (B) predicted cytotoxic T lymphocyte (CTL) levels, (C) tumor mutational burden (TMB), (D) myeloid-derived suppressor cells (MDSC), and (E) cancer associated fibroblast (CAF) abundances across NS-LUAD expression subtypes. Mean values are indicated by the yellow lines. P-values from two-sided Mann-Whitney U-test are shown.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S19 from A Prognostic Signature for Lung Adenocarcinoma in Patients Who Have Never Smoked
Supplementary Figure S19 shows (A) Comparison of TIDE scores predicting response to ICB across NS-LUAD expression subtypes. B-E, Comparison of (B) predicted cytotoxic T lymphocyte (CTL) levels, (C) tumor mutational burden (TMB), (D) myeloid-derived suppressor cells (MDSC), and (E) cancer associated fibroblast (CAF) abundances across NS-LUAD expression subtypes. Mean values are indicated by the yellow lines. P-values from two-sided Mann-Whitney U-test are shown.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from A Prognostic Signature for Lung Adenocarcinoma in Patients Who Have Never Smoked
Supplementary Figure S6 shows violin plots that depict the expression levels of (A) the proliferation marker MKI67, and the mesenchymal markers (B) CDH2 and (C) TWIST1 in tumor samples with estimated purity of greater than 0.8. Mean values are indicated by the yellow lines in the violin plots. P-values from two-sided Mann-Whitney U-test are shown in corresponding figures.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from A Prognostic Signature for Lung Adenocarcinoma in Patients Who Have Never Smoked
Supplementary Figure S6 shows violin plots that depict the expression levels of (A) the proliferation marker MKI67, and the mesenchymal markers (B) CDH2 and (C) TWIST1 in tumor samples with estimated purity of greater than 0.8. Mean values are indicated by the yellow lines in the violin plots. P-values from two-sided Mann-Whitney U-test are shown in corresponding figures.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from A Prognostic Signature for Lung Adenocarcinoma in Patients Who Have Never Smoked
Supplementary Figure S4 shows Summary of (A) IPA and (B) GSEA analyses of differentially expressed genes associated with the steady subtype. C-D, Summary of (C) IPA and (D) GSEA analyses of differentially expressed genes associated with the proliferativesubtype. E-F, Summary of (E) IPA and (F) GSEA analyses of differentially expressed genes associated with the chaoticsubtype. In IPA plots, orange and blue indicate positive and negative associations, respectively. In GSEA plots, bar height represents the normalized enrichment score, bar color indicates the FDR-adjusted p-value (FDR <0.1), and pathway annotations are shown on the left.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from A Prognostic Signature for Lung Adenocarcinoma in Patients Who Have Never Smoked
Supplementary Figure S4 shows Summary of (A) IPA and (B) GSEA analyses of differentially expressed genes associated with the steady subtype. C-D, Summary of (C) IPA and (D) GSEA analyses of differentially expressed genes associated with the proliferativesubtype. E-F, Summary of (E) IPA and (F) GSEA analyses of differentially expressed genes associated with the chaoticsubtype. In IPA plots, orange and blue indicate positive and negative associations, respectively. In GSEA plots, bar height represents the normalized enrichment score, bar color indicates the FDR-adjusted p-value (FDR <0.1), and pathway annotations are shown on the left.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from A Prognostic Signature for Lung Adenocarcinoma in Patients Who Have Never Smoked
Supplementary Table S1 s shows summary of RNA-seq-based studies for NS-LUAD.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from A Prognostic Signature for Lung Adenocarcinoma in Patients Who Have Never Smoked
Supplementary Table S1 s shows summary of RNA-seq-based studies for NS-LUAD.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from A Prognostic Signature for Lung Adenocarcinoma in Patients Who Have Never Smoked
Supplementary Table S2 shows characteristics and clinical data of patients in the Sherlock cohort.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from A Prognostic Signature for Lung Adenocarcinoma in Patients Who Have Never Smoked
Supplementary Table S2 shows characteristics and clinical data of patients in the Sherlock cohort.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10 from A Prognostic Signature for Lung Adenocarcinoma in Patients Who Have Never Smoked
Supplementary Figure S10 shows proportion of fibroblasts and lepidic components with NS-LUAD expression subtypes are indicated by colors. P-value from Pearson correlation test is shown.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S10 from A Prognostic Signature for Lung Adenocarcinoma in Patients Who Have Never Smoked
Supplementary Figure S10 shows proportion of fibroblasts and lepidic components with NS-LUAD expression subtypes are indicated by colors. P-value from Pearson correlation test is shown.